【摘要】 目的研究乌司他丁能否减轻化疗的不良反应并探讨其机制。方法将40例胃肠道肿瘤术后患者随机分成乌司他丁治疗组和空白对照组。所有患者在化疗前1d及下次化疗前空腹抽血检测白介素6(IL-6)和肿瘤坏死因子α(TNF-α)。治疗组患者每天化疗前滴注乌司他丁15万U,连续5d;对照组患者每天化疗前滴注生理盐水;对比两组患者的不良反应发生率和治疗前后IL-6、TNF-α水平的变化。结果两组患者临床病理特征无差别。对照组白细胞下降、皮肤毒性、脱发的发生率比治疗组高,两组比较分别为P=0.049,P=0.026和P=0.032。治疗组患者化疗后IL-6的水平下降,与化疗前比较,P=0.033;TNF-α的水平化疗前后无明显变化。对照组治疗前后IL-6及TNF-α的水平均无明显变化。结论乌司他丁能减轻化疗后的一些常见不良反应,其机制可能是通过降低炎症因子IL-6的水平而发挥作用的。更多还原

【Abstract】 Objective To investigate whether ulinastatin can alleviate the side effect in patients with gastrointestinal cancer undergoing adjuvant chemotherapy,and to explore the probable mechanism of its protective efficacy. Methods Forty consecutive patients with gastrointestinal cancer who underwent surgical operations from May 2004 to October 2004 were recruited. The patients were randomly divided into therapeutic group and control group,receiving ulinastatin 150 000 U per day or 250 ml hydrochloric sodium before chemotherapy for 5 continuous days respectively. The prevalence of side effects and the levels IL-6 and TNF-αwere compared between the two groups. Results There were no differences in the clinicopathological characteristics between the two groups. The prevalences of white blood cell decline(41.2%versus 13.1%),pigmentation(23.5%versus 4.3%),baldness (17.6%versus 4.3%) were higher in the control group than those in therapeutic group(all P< 0.05). In therapeutic group,IL-6 level was significantly decreased after ulinastatin treatment,but not in the control group while the levels of TNF-αwere not changed in the both groups. Conclusion Ulinastatin can reduce the common side effects of chemotherapy,and the mechanism may be associated with the decrease of IL-6.更多还原